For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
7
views
24
references
 Top references
cited by
1
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      1,040
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Tobacco nicotine promotes TRAIL resistance in lung cancer through SNHG5

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tobacco nicotine use is carcinogenic and a well-known risk factor for lung cancer. However, whether tobacco nicotine can induce drug resistance in lung cancer is not clear. The objective of the present study was to identify the TNF-related apoptosis-inducing ligand (TRAIL) resistance of long noncoding RNAs (lncRNAs) that are differentially expressed in smokers and nonsmokers with lung cancer. The results suggested that the nicotine upregulated small nucleolar RNA host gene 5 (SNHG5) and markedly decreased the levels of cleaved caspase-3. The present study found that cytoplasm lncRNA SNHG5 overexpression was associated with TRAIL resistance in lung cancer and that SNHG5 can interact with X-linked inhibitor of apoptosis protein to promote TRAIL resistance. Therefore, nicotine promoted TRAIL resistance in lung cancer through SNHG5/X-linked inhibitor of apoptosis protein.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

          Kenneth Livak, Thomas D. Schmittgen (2001)
          The two most commonly used methods to analyze data from real-time, quantitative PCR experiments are absolute quantification and relative quantification. Absolute quantification determines the input copy number, usually by relating the PCR signal to a standard curve. Relative quantification relates the PCR signal of the target transcript in a treatment group to that of another sample such as an untreated control. The 2(-Delta Delta C(T)) method is a convenient way to analyze the relative changes in gene expression from real-time quantitative PCR experiments. The purpose of this report is to present the derivation, assumptions, and applications of the 2(-Delta Delta C(T)) method. In addition, we present the derivation and applications of two variations of the 2(-Delta Delta C(T)) method that may be useful in the analysis of real-time, quantitative PCR data. Copyright 2001 Elsevier Science (USA).
          Article 0 comments Cited 23444 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The biology and management of non-small cell lung cancer.

            Roy S. Herbst, Daniel Morgensztern, Chris Boshoff (2018)
            Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been achieved over the past two decades, increasing our understanding of the disease biology and mechanisms of tumour progression, and advancing early detection and multimodal care. The use of small molecule tyrosine kinase inhibitors and immunotherapy has led to unprecedented survival benefits in selected patients. However, the overall cure and survival rates for NSCLC remain low, particularly in metastatic disease. Therefore, continued research into new drugs and combination therapies is required to expand the clinical benefit to a broader patient population and to improve outcomes in NSCLC.
            Article 0 comments Cited 1537 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lung cancer: current therapies and new targeted treatments.

              Fred Hirsch, Giorgio Scagliotti, James L Mulshine … (2017)
              Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4-17% depending on stage and regional differences. In this Seminar, we discuss existing treatment for patients with lung cancer and the promise of precision medicine, with special emphasis on new targeted therapies. Some subgroups, eg-patients with poor performance status and elderly patients-are not specifically addressed, because these groups require special treatment considerations and no frameworks have been established in terms of new targeted therapies. We discuss prevention and early detection of lung cancer with an emphasis on lung cancer screening. Although we acknowledge the importance of smoking prevention and cessation, this is a large topic beyond the scope of this Seminar.
              Article 0 comments Cited 1138 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Exp Ther Med
                Journal ID (iso-abbrev): Exp Ther Med
                Journal ID (publisher-id): ETM
                Title: Experimental and Therapeutic Medicine
                Publisher: D.A. Spandidos
                ISSN (Print): 1792-0981
                ISSN (Electronic): 1792-1015
                Publication date Collection: March 2023
                Publication date (Electronic): 10 February 2023
                Publication date PMC-release: 10 February 2023
                Volume: 25
                Issue: 3
                Electronic Location Identifier: 131
                Affiliations
                Department of Oncology, Chaohu Hospital Affiliated to Anhui Medical University, Chaohu, Anhui 231500, P.R. China
                Author notes
                Correspondence to: Professor Xianfeng Shi, Department of Oncology, Chaohu Hospital Affiliated to Anhui Medical University, 64 Chaohu North Road, Juchao, Chaohu, Anhui 231500, P.R. China shixianfeng202010@ 123456163.com
                Article
                Publisher ID: ETM-25-3-11830
                DOI: 10.3892/etm.2023.11830
                PMC ID: 9947578
                PubMed ID: 36845946
                SO-VID: ebc5bed4-3b3d-47fe-9c54-132327ca7322
                Copyright © Copyright: © Xiao et al.
                License:

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

                History
                Date received : 13 June 2022
                Date accepted : 27 October 2022
                Funding
                Funding: This study was supported by a grant from the Anhui Medical University Project Fund (grant no. 2021xkj188).
                Categories
                Subject: Articles

                ScienceOpen disciplines: Medicine
                Keywords: small nucleolar rna host gene 5,lung cancer,tnf-related apoptosis-inducing ligand resistance,apoptosis
                Data availability:
                ScienceOpen disciplines: Medicine
                Keywords: small nucleolar rna host gene 5, lung cancer, tnf-related apoptosis-inducing ligand resistance, apoptosis

                Comments

                Comment on this article